COMMUNIQUÉS West-GlobeNewswire

Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC
06/11/2018
CHARLESTON, S.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc. agreeing to make a payment to [...]
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
06/11/2018
38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody Median Duration of Response (DOR) of 6.4 Months Data selected for [...]
Transactions in relation to share buyback program
06/11/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer’s Disease
06/11/2018
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences [...]
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
06/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Kura Oncology to Participate in Two Upcoming Investor Conferences
06/11/2018
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy [...]
OpGen Completes Specimen Accrual and Testing in Acuitas® Clinical Verification Study
06/11/2018
Study evaluated potential utility in management of complicated urinary tract infections; Analysis and peer-reviewed manuscript preparation are underway GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. ( [...]
Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
06/11/2018
PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today [...]
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06/11/2018
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development [...]
Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
06/11/2018
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the [...]
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
06/11/2018
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with [...]
Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors
06/11/2018
DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned biopharmaceutical executive Markus [...]
AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
06/11/2018
ALACHUA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced [...]
Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results
06/11/2018
BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Microbix Exhibiting at MEDICA Trade Fair
06/11/2018
Showcasing Antigen and Quality Assessment Products TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix ® ), an innovator of biological products and technologies, announces that it [...]
G1 Therapeutics to Present at Investor Conferences in November 2018
06/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will [...]
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
06/11/2018
THE WOODLANDS, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief [...]
Akcea Therapeutics to Present at Upcoming Investor Conferences
06/11/2018
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare [...]
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, [...]

Pages